Monitor the August 6 earnings call for enrollment timeline updates and potential guidance on study completion. The rapid enrollment de-risks the pivotal study timeline, which could support near-term upside if momentum continues.
Price Chart
Executive Summary
Pulse Biosciences announced it has surpassed the enrollment midpoint of its NANOPULSE-AF pivotal IDE study evaluating the nPulse Cardiac Catheter System for paroxysmal atrial fibrillation. The study, which began in April 2026, is enrolling at up to 30 sites and rapid enrollment signals strong investigator interest. The company will provide further commentary on its August 6 earnings call.
Key Facts
- Surpassed enrollment midpoint of NANOPULSE-AF pivotal IDE study for nPulse Cardiac Catheter System
- Study commenced in April 2026 and targets up to 30 sites including international locations
- Rapid enrollment reflects investigator enthusiasm per CMO and top-enrolling investigator quotes
- Additional commentary expected on August 6, 2026 earnings conference call
Financial Impact
No financial figures disclosed; positive pipeline milestone supports valuation of nPulse technology
Risk Factors
- Clinical trial risks: enrollment slowdown, safety/efficacy data not yet available
- Regulatory approval uncertainty: FDA clearance required for commercialization
- Competitive landscape in pulsed field ablation for atrial fibrillation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-024758 |
| Exhibit: ex_994535.htm | 0001437749-26-024758 |
| Document: 0001437749-26-024758-index-headers.html | 0001437749-26-024758 |
| Document: 0001437749-26-024758-index.html | 0001437749-26-024758 |
| Document: 0001437749-26-024758.txt | 0001437749-26-024758 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $46.32 | awaiting T+60 | — | $53.12 (+14.69%) |
Oct 7, 2026 20d ago | 8-K | $49.09 | awaiting T+60 | — | $53.12 (+8.21%) |
Sep 15, 2026 6w ago | 8-K | $55.20 | awaiting T+60 | — | $53.12 (−3.76%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $53.12 (−25.26%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $53.12 (−25.26%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $53.12 (+55.10%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $53.12 (+117.98%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $53.12 (+112.58%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $53.12 (+107.43%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $53.12 (+178.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers